Physician profile
Christopher J Corder
NPI 1871857219
$2,475.46
in general payments reported to CMS, 2019-2025
27 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $316 · 2021: $369 · 2022: $462 · 2023: $471 · 2024: $195 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.88 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $452.27 | 2019-2023 | Ams 700 Cxr Rte Kit |
| Teleflex LLC | $360.30 | 2021-2023 | Urolift |
| Endo Pharmaceuticals INC. | $188.82 | 2019-2023 | Xiaflex, Aveed |
| Karl Storz Endoscopy-America | $165.67 | 2019-2020 | |
| Endo USA, INC. | $141.11 | 2024-2025 | Xiaflex, Aveed, Edex |
| Antares Pharma, INC. | $140.34 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Sumitomo Pharma America, INC. | $120.47 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $114.76 | 2019-2022 | |
| Myovant Sciences INC. | $93.69 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $91.94 | 2022-2024 | Trelstar |
| Ferring Pharmaceuticals INC. | $65.28 | 2019-2025 | Adstiladrin |
| Accord Healthcare, INC. | $57.76 | 2022 | |
| Merck Sharp & Dohme LLC | $51.72 | 2022-2023 | Lynparza, Keytruda |
| Dendreon Pharmaceuticals LLC | $45.68 | 2019-2025 | Provenge |
| Coloplast Corp | $45.33 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $43.63 | 2024-2025 | Eligard, Jatenzo |
| Halozyme INC | $41.22 | 2023 | |
| Sun Pharmaceutical Industries INC. | $37.89 | 2024-2025 | |
| Allergan, INC. | $35.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Urogen Pharma, INC. | $29.51 | 2021-2022 | |
| Pfizer INC. | $29.48 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.01 | 2022 | |
| Travere Therapeutics, INC. | $21.34 | 2020 | |
| Myriad Genetic Laboratories, INC. | $15.00 | 2023 | Prolaris |
| Abbvie INC. | $14.38 | 2024 | |
| Neotract INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Corder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.